MedPath
HSA Product

NOXBETA TABLET 5 MG

Product approved by Health Sciences Authority (SG)

Basic Information

NOXBETA TABLET 5 MG

TABLET

Regulatory Information

SIN16486P

May 6, 2022

Prescription Only

Therapeutic

ORAL

August 10, 2023

June 3, 2025

XC07AB12

Company Information

A. MENARINI SINGAPORE PTE. LTD.

A. MENARINI SINGAPORE PTE. LTD.

Active Ingredients

Detailed Information

Contraindications

**Contraindications** - Hypersensitivity to the active substance or to any of the excipients. - Liver insufficiency or liver function impairment. - Pregnancy and lactation. - Acute heart failure, cardiogenic shock or episodes of heart failure decompensation requiring i.v. inotropic therapy. In addition, as with other beta-blocking agents, Noxbeta is contra-indicated in: - sick sinus syndrome, including sino-atrial block. - second and third degree heart block (without a pacemaker). - history of bronchospasm and bronchial asthma. - untreated phaeochromocytoma. - metabolic acidosis. - bradycardia (heart rate < 60 bpm prior to start therapy). - hypotension (systolic blood pressure < 90 mmHg). - severe peripheral circulatory disturbances.

Indication Information

**THERAPEUTIC INDICATIONS** Hypertension Treatment of essential hypertension. Chronic heart failure (CHF) Treatment of stable mild and moderate chronic heart failure in addition to standard therapies in elderly patients > 70 years.

© Copyright 2025. All Rights Reserved by MedPath